medigraphic.com
Colegio de Medicina Interna de México.

2018, Number 2

<< Back Next >>

Med Int Mex 2018; 34 (2)

Differences in electrocardiographic changes in HIV patients with and without treatment with protease inhibitors vs NNRTI

Hernández-Pilotzi G, Huerta-Vargas D, Cerda-Téllez F, Martínez-Nava AG, Lozada-Pérez CA

Language: Spanish
References: 21
Page: 204-213
PDF size: 448.77 Kb.


ABSTRACT

Background: Human immunodeficiency virus (HIV) infection increases the prevalence of QTc prolongation (QTc), which is an independent factor of cardiovascular disease events in this population. In the world literature this change is associated with the use of the protease inhibitors and efavirenz antiretrovirals. However, no data are available on these changes in the Mexican population.
Material and Method: A prospective observational study was done selecting records from March 2015 to May 2016 of the external consultation of the National Institute of Respiratory Diseases (INER), Mexico City; they were divided into two groups, those without treatment, because recent diagnosis, and with antiretroviral treatment. We recorded clinical data, pharmacological treatment, electrocardiogram and blood chemistry.
Results: We found no differences between the two groups regarding age or serum electrolytes. We found no association between QTc prolongation and efavirenz or protease inhibitors. Raltegravir decreased QTc duration (p = 0.001) while molluscum contagiosum coinfection was associated with QTc prolongation (p = 0.02).
Conclusion: In our study, we failed to demonstrate in Mexican population association of QTc prolongation with first- and secondline antiretrovirals. More studies are needed to determine the clinical significance of the effect of raltegravir and molluscum contagiosum on QTc.


REFERENCES

  1. Sliwa K, Carrington M, Becker A, Thienemann F, Ntsekhe M, Stewart S. Contribution of the human immunodeficiency virus/acquired immunodeficiency syndrome epidemic to de novo presentations of heart disease in the Heart of Soweto Study cohort. Eur Heart J 2012;33:866-874.

  2. Twu C, Liu N, Popik W, Bukrinsky M, et al. Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways; Medical sciences PNAS, 2002;99(22):14386-14391.

  3. Zirpoli J, Ramos H, Gonςalves V, Pessoa M, De Barros D, Soares V. Angina pectoris in patients with HIV/AIDS: prevalence and risk factors. Braz J Infect Dis 2012;16(1):1-8.

  4. Ogunmola O, Oladosu Y, Olamoyegun M. QTc interval prolongation in HIV-negative versus HIV-positive subjects with or without antiretroviral drugs. Ann African Med 2015;14:169-176.

  5. Nachimuthu S, Assar M, Schussler J. Drug-induced QT interval prolongation: mechanisms and clinical management. Thr Adv Drug Safety 2012;3:241-253.

  6. Dawood F, Roediger M, Grandits G, Miller D, et al. Determinants of developing widened spatial QRS-T angle in HIV-infected individuals: Results from the Strategies for Management of Antiretroviral Therapy [SMART] Study. J Electrocardiol 2014;47(2):264-271.

  7. Moreno T, Pérez I, Isasti G, Cabrera F, Santos J, Palacios R. Prevalence and factors associated with a prolonged QTc interval in a cohort of asymptomatic HIV-infected patients. AIDS Research and Human Retroviruses 2013;29(9):1195- 1198.

  8. AIDS info. Food and Drug Administration label.

  9. Gupta M, Miller CJ, Baker JV, Lazar J, et al. Biomarkers and electrocardiographic evidence of myocardial ischemia in patients with human immunodeficiency virus infection. Am J Cardiol 2013;111(5):760-764.

  10. Li J, Menard V, Benish RL, Juveric RJ, et al. Worldwide variation in human drug-metabolism enzyme genes CYB2B6 and UGT2B7: implications for HIV/AIDS treatment, Pharmacogenomics 2012;13:555-570.

  11. Schneider S, Muller-Chorus A, Pennekamp W. Acute ventricular fibrillation during primary HIV infection. Int J STD & AIDS 2012;23(6): 443-445.

  12. Soliman E, Prineas R, Roediger M, Duprez D, et al. Prevalence and prognostic significance of ECG abnormalities in HIV-infected patients: results from the Strategies for Management of Antiretroviral Therapy study. Am J Electrocardiogram 2011;44(6):779-785.

  13. Trinkley KE, Page RL 2do, Lien H, Yamanouye K, Tisdale JE. QT interval prolongation and the risk of torsades de pointes: essentials for clinicians. Current Med Res Opin 2013;29:1719-1726

  14. Patel N, Veve M, Kwon S, McNutt LA, et al. Frequency of electrocardiogram testing among HIV-infected patients at risk for medication-induced QTc prolongation. HIV Medicine 2013;14(8):463-471.

  15. Wayne R, Murray K, Hall K, Arbogast P, Stein M. Azithromycin and the risk of cardiovascular death. N Engl J Med 2012;366:1881-1890.

  16. Chinello P, Lisera FP, Angeletti C, Boumis E, et al. Role of antiretroviral treatment in prolonging QTc interval in HIVpositive patients. J Infect Br 2007;54:597-602.

  17. Soliman EZ, Roediger MP, Duprez DA, Knobel H, et al. Protease inhibitors and cardiac autonomic function in HIV-infected patients: a cross-sectional analysis from the Strategies for Management of Antiretroviral Therapy (SMART) Trial. BMJ Open 2013;6(3):10-16.

  18. Fiorentini A, Petrosillo N, Di Stefano A, Cicalini S, Borgognoni L, Boumis E, et al. QTc interval prolongation in HIVinfected patients: a case-control study by 24-hour Holter ECG recording. BMC Cardiovasc Disord 2012 Dec 23;12:124. doi: 10.1186/1471-2261-12-124.

  19. Kohler J, Hosseini S, Lewis W. Mitochondrial DNA impairment in NRTIs-associated Cardiomyopathy. Chem Res Toxicol 2008;21(5):990-996.

  20. Petrosillo N, Lisena FP, Chinello P. QTc prolongation in human immunodeficiency virus-infected persons. Arch Intern Med. 2006 Nov 13;166(20):2288-9.

  21. Nordin C, Kohli A, Beca S, Zaharia V, Grant T, Leider J, Marantz P. Importance of hepatitis C coinfection in the development of QT prolongation in HIV-infected patients. J Electrocardiol. 2006 Apr;39(2):199-205. Epub 2005 Nov 28.




2020     |     www.medigraphic.com